经尿道前列腺等离子剜除术治疗口服抗凝剂的BPH患者的安全性和疗效  

Safety and efficacy of transurethral plasma prostate enucleation in patients with benign prostatic hyperplasia treated with oral anticoagulants

作　　者：何兆飞[1] 施东辉[1] 杨祖佑[1] 杜春明 宋嘉胤 He Zhaofei;Shi Donghui;Yang Zuyou;Du Chuming;Song Jiayin(Department of Urology,Suzhou Wuzhong People′s Hospital,Suzhou 215128,China)

机构地区：[1]江苏省苏州市吴中人民医院泌尿外科,苏州215128

出　　处：《国际泌尿系统杂志》2024年第6期1001-1004,共4页International Journal of Urology and Nephrology

摘　　要：目的探讨经尿道前列腺等离子剜除术治疗口服抗凝剂的良性前列腺增生(BPH)患者的安全性和疗效。方法回顾性分析2019年8月至2022年7月本院收治的58例BPH患者的临床资料,将其中21例长期口服抗凝剂患者作为观察组,37例未服用抗凝剂患者作为对照组。比较两组患者的临床资料。结果两组患者的手术时间、膀胱冲洗时间、术后国际前列腺症状评分(IPSS)、生活质量评分(QOL)、最大尿流率(Q max)等比较,差异均无统计学意义(均P>0.05)。对照组的术后导尿管留置时间、术后住院时间短于观察组(均P<0.05)。观察组的并发症发生率为23.8%;对照组的并发症发生率为24.3%。两组均无尿道狭窄和包膜穿孔发生。结论经尿道前列腺等离子剜除术治疗长期口服抗凝剂的BPH患者安全有效,值得临床推广应用。ObjectiveTo investigate the safety and efficacy of transurethral plasma enucleation of prostate in the treatment of oral anticoagulants with benign prostatic hyperplasia(BPH).MethodsThe clinical data of 58 BPH patients admitted to our hospital from August 2019 to July 2022 were retrospectively analyzed,including 21 patients with long-term oral anticoagulants as the observation group and 37 patients without anticoagulants as the control group.The clinical data of the two groups were compared.ResultsThere were no significant differences in operation time,bladder irrigation time,International Prostate Symptom Score(IPSS),quality of life(QOL)and maximum flow rate(Q max),etc.,between the two groups(all P>0.05).The postoperative catheter retention time and postoperative hospitalization time in control group were shorter than those in observation group(P<0.05).The incidence of complications in the observation group was 23.8%.The complication rate in the control group was 24.3%.No urethral stricture and capsule perforation occurred in both groups.ConclusionsTransurethral plasma enucleation of prostate in the treatment of long-term oral anticoagulant combined with prostatic hyperplasia is safe and effective,worthy of clinical application.

关 键 词：前列腺增生 前列腺切除术 抗凝药 

分 类 号：R699.8[医药卫生—泌尿科学]